SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

by DIACOUSTIC MEDICAL DEVICES (PTY)

EchoNext

by Pathway Labs

AI Verdict

Both tools are FDA-cleared AI solutions in cardiology, offering clinical decision support. SensiCardiac Mobi focuses on real-time heart murmur analysis using electronic stethoscopes, aiding in the differentiation of physiological and pathological sounds. EchoNext, conversely, analyzes standard ECGs to detect hidden structural heart disease, including heart failure and valve disease, providing a broader diagnostic scope for underlying conditions.

Choose SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION if…

Choose SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION if you need an AI-powered mobile solution to assist in the real-time diagnosis of heart murmurs during physical examinations. This tool is ideal for physicians who want to differentiate between physiological and pathological heart sounds by analyzing acoustic signals from an electronic stethoscope, particularly in settings like sports physicals or routine check-ups where immediate assessment of murmurs is crucial.

View SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION →

Choose EchoNext if…

Choose EchoNext if you need an AI tool to analyze standard ECGs for the early detection of hidden structural heart disease, including conditions like heart failure, valve disease, and pulmonary hypertension. This tool is best suited for broad screening in various clinical settings, from major hospitals to community practices, to identify patients at high risk who should undergo further evaluation with an echocardiogram.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Hosted server environment (Linux OS) with a mobile application interface	Available through the OpenEvidence clinical decision support platform.
BAA Available	Yes AI-estimated	Yes AI-estimated
FDA Status	1 AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION

SensiCardiac Mobi leverages a dedicated mobile application interface (iPhone 4S or later) for data capture and display, suggesting a highly portable and immediate point-of-care experience. This mobile-first approach for heart murmur diagnosis likely offers a more intuitive and accessible user experience for quick assessments compared to a PC-installed software.

Clinical Value

EchoNext

EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, with reported higher accuracy (77%) than cardiologists (64%) in a head-to-head comparison. SensiCardiac Mobi assists in diagnosing heart murmurs by differentiating physiological and pathological sounds, but a comparative study showed it had lower sensitivity (69%) and specificity (54%) than a newer mobile application for murmur detection.

Pricing & Value

EchoNext

EchoNext offers tiered pricing starting at $600/month, with clear details on different plans, implementation fees, and annual discounts, providing transparency for potential buyers. In contrast, SensiCardiac Mobi's pricing is not publicly available, requiring direct contact for information, which makes it harder to assess its value proposition without further engagement.

Enterprise Readiness

EchoNext

EchoNext is available through the OpenEvidence clinical decision support platform, which is used by 650,000 U.S. physicians, indicating a broader integration and deployment capability within existing healthcare IT infrastructures. SensiCardiac Mobi operates on a hosted server environment with a mobile application interface, which, while functional, doesn't explicitly detail the same level of platform integration or broad access for enterprise environments.

Innovation

EchoNext

EchoNext represents a significant innovation by being the world's first FDA-cleared AI tool to detect hidden structural heart disease from standard ECGs, a capability traditionally not possible with ECGs alone. SensiCardiac Mobi, while innovative in its mobile AI-powered heart murmur diagnosis, addresses a more established diagnostic area.

Support & Docs

Tie

Neither tool provides specific details about their customer support channels, service level agreements, or the extent of their documentation (e.g., user manuals, developer guides, FAQs) in the provided information or readily available web searches. Therefore, it is not possible to determine a winner in this dimension.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION	EchoNext
Tool Name	SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION	EchoNext
Company	DIACOUSTIC MEDICAL DEVICES (PTY)	Pathway Labs
Description	FDA-cleared AI-powered mobile application that assists physicians in diagnosing heart murmurs by analyzing acoustic heart signals from an electronic stethoscope to differentiate between physiological and pathological sounds.	FDA-cleared AI tool from Pathway Labs that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Functionality	Analyzes acoustic heart signals to differentiate between physiological and pathological heart murmurs, identifies S1, S2, and suspected murmurs.	Analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Required Input	Compatible electronic stethoscope (user-provided)	Standard 12-lead ECGs
Specialties	Cardiology, Internal Medicine, Pediatrics	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring SENSICARDIAC MOBI DIAGNOSTIC HEART MURMUR APPLICATION and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

SensiCardiac Mobi is a mobile application that acquires and records heart sounds using a compatible electronic stethoscope, operating as decision support software that complements physician assessment. EchoNext integrates with the OpenEvidence clinical decision support platform, which is used by many physicians, to make its AI-powered ECG analysis available at the point of care.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

SensiCardiac Mobi has demonstrated a sensitivity of 84% and a specificity of 94% in distinguishing between physiological and pathological heart murmurs. EchoNext has shown high accuracy, identifying 77% of structural heart problems from ECGs alone, compared to 64% for cardiologists without AI assistance. In a prospective pilot study, EchoNext identified previously unrecognized structural heart disease in 73% of high-risk participants.

What is the learning curve for physicians to effectively use each tool?

The SensiCardiac Mobi software's graphical user interface is nearly identical to a previous FDA-cleared version, and usability studies showed users scored it highly, suggesting a manageable learning curve. For EchoNext, while specific learning curve data for physicians isn't detailed, its integration into the widely used OpenEvidence platform suggests an aim for broad accessibility and ease of use within existing physician workflows.

What kind of support and resources are available for physicians using these tools?

While specific details on support quality are not provided for SensiCardiac Mobi, its FDA clearance and nature as a medical device imply standard support for technical and operational aspects. EchoNext is deployed through OpenEvidence, a platform that aims to provide high-quality, high-impact technology to physicians without significant delays, suggesting readily available support through that platform.

Can these tools be easily rolled out across multiple clinical sites or a large healthcare system?

SensiCardiac Mobi operates with a mobile application and a hosted server environment, which could facilitate multi-site deployment, though specific rollout considerations are not detailed. EchoNext is designed for broad access, from major hospitals to community practices, and its availability through the OpenEvidence platform supports widespread deployment across various care settings.

What clinical context should guide a physician's choice between SensiCardiac Mobi and EchoNext?

SensiCardiac Mobi is designed to assist in diagnosing heart murmurs by analyzing acoustic heart signals from an electronic stethoscope, differentiating between physiological and pathological sounds. It is useful for routine physical examinations where an asymptomatic cardiac murmur is heard. EchoNext analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension, and is intended for earlier detection of conditions that might otherwise go undiagnosed until symptomatic. It can help triage patients for further imaging like echocardiograms.

What audit-trail features are available to track the use and decisions made by these AI tools?

The provided information does not explicitly detail specific audit-trail features for either SensiCardiac Mobi or EchoNext. However, as medical devices and decision support software, both would typically adhere to regulatory expectations for data logging and traceability, though the specifics of these features are not outlined.